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Aspirin, acetylsalicylic acid, was synthesized by Hoffman
of Bayer Laboratories in 1897. Aspirin irreversibly in-
hibits platelet cyclooxygenase (COX-1) activity, thus
preventing the synthesis of thromboxaneA2, and thereby
inhibiting platelet aggregation and thrombi formation.
A low dose of aspirin, commonly defined as 75–325mg
daily, is effective in preventing cardiovascular (CV)
and cerebrovascular disease with decreasing vascular
mortality.1 Meta-analysis data including 142 random-
ized trials involving approximately 100,000 patients
at risk of vascular events showed that aspirin (75–
150 mg/day) reduces by 25% the incidence of ischemic
stroke, myocardial infarction, and vascular death when
compared with placebo.2 The efficacy of low-dose
aspirin for secondary prevention of CV disease is well
documented. However, studies investigating the use
of aspirin in primary prevention have produced
inconsistent results.
The major factor limiting the use of aspirin is con-
cern about the development of gastrointestinal (GI)
events, especially GI ulcer and bleeding due to its inhi-
bition of prostaglandin formation in GI mucosa. 
A study showed that low-dose aspirin (75–325mg/day)
for 3 months was associated with a 7% incidence of
endoscopic gastroduodenal ulcer.3 The use of low-
dose aspirin is associated with a 2- to 4-fold increased
risk of upper GI (UGI) events. The pooled incidence
of major GI bleeding in a meta-analysis of several
placebo-controlled trials, using aspirin 75–325mg daily,
was 0.12% per year (95% confidence interval, 0.07–
0.19), with an odds ratio (OR) of 2.07.4 This means
that 833 patients would need to be treated with low-
dose aspirin rather than no aspirin to cause an addi-
tional episode of major GI bleeding over 1 year. But
in high-risk patients who had a past history of aspirin-
related ulcer bleeding, a very high rate of recurrent
ulcer bleeding (15%) within 1 year was noted when
they continued to take aspirin for cardioprevention after
their ulcers had healed and Helicobacter pylori (Hp) had
been eradicated.5 Elderly patients, history of peptic
ulcer or ulcer bleeding, Hp infection, concomitant
use of steroid, anticoagulant, and nonsteroidal anti-
inflammatory drugs (NSAIDs) are all risk factors for
ulcer bleeding in aspirin users. The ulcerogenic effects
of aspirin are systemic rather than topical, which is
supported by several studies showing no difference in
UGI bleeding occurrence between enteric coated or
uncoated aspirin. Observational studies showed an asso-
ciation between higher aspirin dose and risk of UGI
complications. The 2008 ACG and AHA expert con-
sensus document recommends lowering the dose from
325 mg to 81 mg among those with a high risk of UGI
events. However, it is unknown what the optimal
dose of aspirin really is.6
Three key strategies have been proposed for mini-
mizing the UGI side effect of low-dose aspirin. These
are the use of an alternative platelet inhibitor, such as
clopidogrel, the use of co-therapy with a gastropro-
tective agent, such as proton pump inhibitor (PPI),
and strong consideration of Hp eradication.7
Clopidogrel is an alternative antiplatelet agent that
inhibits adenosine diphosphate-induced platelet aggre-
gation through irreversible inhibition of P2 nucleotide
receptors on the platelet surface. Clopidogrel does not
inhibit COX function and prostaglandin formation
and does not cause endoscopically evident mucosal
injury in healthy volunteers. It is commonly used for
secondary CV prevention in place of low-dose aspirin
in patients who have experienced GI intolerance to
aspirin-related adverse events or with aspirin allergy.
Inconsistent results from population-based observa-
tional studies and case-control studies have been found
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with regard to whether clopidogrel is safer than aspirin
for GI bleeding. The CAPRIE trial showed that clopi-
dogrel 75 mg/day significantly lowered all GI bleeding
and severe GI bleeding and significantly reduced the
risk of ischemic stroke, myocardial infarction and is-
chemic death when compared with aspirin 325mg/day
in high-CV-risk patients.8 However, clopidogrel is
not safe enough for patients with high GI risk. Eight
to 13% of patients developed recurrent ulcer bleeding
within 1 year when they took clopidogrel instead of
aspirin after their ulcers had healed and Hp had been
eradicated, while only 1% of patients developed recur-
rent ulcer bleeding when they used aspirin combined
with PPI after their ulcers had healed and Hp had
been eradicated.9,10 The 2008 ACG and AHA expert
consensus document recommends that substitution of
clopidogrel for aspirin is not recommended strategy
to reduce the risk of recurrent ulcer bleeding in high-
risk patients and is inferior to the combination of aspirin
and PPI.6 It appears that impairment of ulcer healing
by inhibition of platelet aggregation and angiogenesis
may be the mechanism by which antiplatelet agents may
cause existing asymptomatic ulcers to bleed. Thus, while
such agents may not be the primary cause of ulcers,
they may impair healing of background ulcers.11
PPI, which reduces gastric acid secretion, plays a
protective role in aspirin or other NSAID-associated
mucosal damage. One observational study reported 
a low incidence of UGI complications (1 event/100
patients/year) among high-GI-risk patients receiving
low-dose aspirin plus PPI.12 PPI is effective in pre-
venting aspirin-associated recurrent ulcer bleeding after
Hp eradication and ulcers have healed.5 In aspirin users
who have a history of UGI bleeding and Hp infec-
tion, PPI is equivalent to Hp eradication in preventing
recurrent ulcer bleeding.13 A recent study revealed that
PPI co-therapy in patients taking long-term low-dose
aspirin for secondary CV prevention was cost-effective.14
Misoprostol, an analog of prostaglandin E1, is 
also effective in reducing endoscopic gastric erosions
in healthy volunteers taking aspirin 300 mg/day.
However, the major limitation in using misoprostol is
diarrhea, which causes poor compliance. Observa-
tional case-control studies in low-dose aspirin users
reported a decreased risk of UGI bleeding (OR, 0.4–
0.5) when they took histamine receptor 2 antagonists
concomitantly.15
Hp infection is an important factor for ulcer and
ulcer bleeding in the general population. Case-
controlled studies have consistently shown that Hp is
an important risk factor for ulcer and ulcer bleeding
in low-dose aspirin users. However, whether Hp erad-
ication alone would adequately reduce the risk of
ulcer bleeding in aspirin users with high GI risk is
uncertain.15 A more recent study, and the largest one to
date, suggested that confirmed Hp eradication in aspirin
users with prior ulcer bleeding significantly reduces
the risk of recurrent bleeding.16 Therefore, before start-
ing long-term therapy with antiplatelet agents, testing
for and eradicating Hp in patients with a history of
ulcer disease is recommended by the 2008 ACG and
AHA expert consensus document.6
In conclusion, low-dose aspirin therapy for CV
prophylaxis is associated with an increased risk of devel-
oping UGI events. The use of non-aspirin antiplatelet
agents as an alternative in patients with GI risk may
also cause undesirable UGI effects. Hp infection has
been identified as a clear risk factor in patients taking
low-dose aspirin. Current data suggest that PPI seems
to be the best choice in reducing UGI events associ-
ated with low-dose aspirin therapy in high-GI-risk
patients, but concomitant Hp eradication may be of
additional benefit in all patients, especially in those
with previous ulcer history.
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